All In Biotech

NDA 204242 · Edenbridge Pharms

Zubsolv

Buprenorphine Hydrochloride, Naloxone Hydrochloride · Sublingual

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jul 3, 2013

Approved uses

3

Original approval plus efficacy supplements

Registered trials

512

125 Phase 3, 43 recruiting

FAERS reports

1,367

469 serious, 15 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 12, 2026.

ZUBSOLV is indicated for treatment of opioid dependence. ZUBSOLV should be used as part of a complete treatment plan that includes counseling and psychosocial support. ZUBSOLV contains buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist, and is indicated for treatment of opioid dependence. ( 1 ) ZUBSOLV should be used as part of a complete treatment plan that includes counseling and psychosocial support. ( 1 )

Mechanism: ZUBSOLV contains buprenorphine and naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is a potent antagonist at mu-opioid receptors and produces opioid withdrawal signs and symptoms, if administered parenterally, in individuals physically dependent on full opioid agonists.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 4, 2016 Supplement 7 · Efficacy LetterLabel
  • Aug 10, 2015 Supplement 4 · Efficacy LabelLetter
  • Jul 3, 2013 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewOther
6 products under this application
  • ZUBSOLV · BUPRENORPHINE HYDROCHLORIDE EQ 1.4MG BASE; NALOXONE HYDROCHLORIDE EQ 0.36MG BASE · TABLET, SUBLINGUAL · Prescription
  • ZUBSOLV · BUPRENORPHINE HYDROCHLORIDE EQ 0.7MG BASE; NALOXONE HYDROCHLORIDE EQ 0.18MG BASE · TABLET, SUBLINGUAL · Prescription
  • ZUBSOLV · BUPRENORPHINE HYDROCHLORIDE EQ 11.4MG BASE; NALOXONE HYDROCHLORIDE EQ 2.9MG BASE · TABLET, SUBLINGUAL · Prescription
  • ZUBSOLV · BUPRENORPHINE HYDROCHLORIDE EQ 5.7MG BASE; NALOXONE HYDROCHLORIDE EQ 1.4MG BASE · TABLET, SUBLINGUAL · Prescription
  • ZUBSOLV · BUPRENORPHINE HYDROCHLORIDE EQ 2.9MG BASE; NALOXONE HYDROCHLORIDE EQ 0.71MG BASE · TABLET, SUBLINGUAL · Prescription
  • ZUBSOLV · BUPRENORPHINE HYDROCHLORIDE EQ 8.6MG BASE; NALOXONE HYDROCHLORIDE EQ 2.1MG BASE · TABLET, SUBLINGUAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Buprenorphine" as an intervention, any sponsor and status, largest first.

All 512 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence201
  • drug withdrawal syndrome140
  • nausea135
  • wrong technique in product usage process115
  • headache86
  • vomiting86
  • drug ineffective81
  • anxiety76
  • pain73
  • drug withdrawal syndrome neonatal72
  • foetal exposure during pregnancy71
  • off label use68

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20135
201429
201552
2016101
2017150
2018213
2019149
2020140
2021151
202274
202388
202464
202578
202672

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zubsolv (Buprenorphine HCl/Naloxone HCl)

2024 spending

$25.8M

Beneficiaries

5,708

49,425 claims

Per beneficiary

$4,517

$11.15 per unit

View as table
YearSpending
2020$30,098,649
2021$27,785,931
2022$26,416,648
2023$28,116,817
2024$25,785,738

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,775 on PubMed

Sponsor: Edenbridge Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.